Phaseline

Targets › GRM5

GRM5 (Metabotropic glutamate receptor 5): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Psychiatry, Neurology; next expected readout Feb 2027.

G protein-coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. (UniProt, P41594)

Open in Phaseline: the race on GRM5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Noema PharmaBasimglurant (NOE-101)
Metabotropic glutamate receptor 5 modulator
GRM5Phase 2Trigeminal NeuralgiaFeb 2027
Yale UniversityMavoglurant
Metabotropic glutamate receptor 5 antagonist
GRM5Phase 1Alcohol ConsumptionMay 2028

Conditions

Alcohol Consumption (1) Trigeminal Neuralgia (1)

Modalities

small molecule (2)

Companies

Yale University (1) Noema Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.